Decorin biology, expression, function and therapy in the cornea

Current Molecular Medicine

Volumn 11, Issue 2, 2011, Pages 110-128

  Mohan, R R ^a,b,c   Tovey, J C K ^a,b   Gupta, R ^a,b   Sharma, A ^a,b   Tandon, A ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b University of Missouri   (United States)

^c UNIVERSITY OF MISSOURI   (United States)

Author keywords

Cornea; Corneal haze scarring; Decorin; Gene therapy; Tgf beta

Indexed keywords

COLLAGEN; DECORIN; EPIDERMAL GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; CELL CYCLE PROGRESSION; CORNEA; CORNEA INJURY; CORNEA OPACITY; EXTRACELLULAR MATRIX; GENE MUTATION; GENE THERAPY; HUMAN; NEOPLASM; NONHUMAN; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SCAR; TISSUE INJURY; VISUAL DISORDER; WOUND HEALING;

EID: 79952806081     PISSN: 15665240     EISSN: None     Source Type: Journal    
DOI: 10.2174/156652411794859241     Document Type: Article

References (124)

1. Schonherr E, Hausser HJ. Extracellular matrix and cytokines: a functional unit. Dev Immunol 2000; 7: 89-101.
2. Kresse H, Schonherr E. Proteoglycans of the extracellular matrix and growth control. J Cell Physiol 2001; 189: 266-74.
3. Seidler DG, Dreier R. Decorin and its galactosaminoglycan chain: extracellular regulator of cellular function? IUBMB Life 2008; 60: 729-33.
4. Jarvelainen H, Sainio A, Koulu M, Wight TN, Penttinen R. Extracellular matrix molecules: potential targets in pharmacotherapy. Pharmacol Rev 2009; 61: 198-223.
5. Rada JA, Cornuet PK, Hassell JR. Regulation of corneal collagen fibrillogenesis in vitro by corneal proteoglycan (lumican and decorin) core proteins. Exp Eye Res 1993; 56:635-48.
6. Jarvelainen H, Puolakkainen P, Pakkanen S, et al. A role for decorin in cutaneous wound healing and angiogenesis. Wound Repair Regen 2006; 14: 443-52.
7. Tandon A, Tovey JC, Sharma A, Gupta R, Mohan RR. Role of transforming growth factor Beta in corneal function, biology and pathology. Curr Mol Med 2010; 10: 565-78.
8. Mohan RR, Gupta R, Mehan MK, Cowden JW, Sinha S. Decorin transfection suppresses profibrogenic genes and myofibroblast formation in human corneal fibroblasts. Exp Eye Res 2010; 91: 238-45.
9. Handley CJ, Samiric T, Ilic MZ. Structure, metabolism, and tissue roles of chondroitin sulfate proteoglycans. Adv Pharmacol 2006; 53: 219-32.
10. Santra M, Reed CC, Iozzo RV. Decorin binds to a narrow region of the epidermal growth factor (EGF) receptor, partially overlapping but distinct from the EGF-binding epitope. J Biol Chem 2002; 277: 35671-681.
11. Mauviel A, Korang K, Santra M, Tewari D, Uitto J, Iozzo RV. Identification of a bimodal regulatory element encompassing a canonical AP-1 binding site in the proximal promoter region of the human decorin gene. J Biol Chem 1996; 271: 24824-29.
12. Stander M, Naumann U, Wick W, Weller M. Transforming growth factor-beta and p-21: multiple molecular targets of decorin-mediated suppression of neoplastic growth. Cell Tissue Res 1999; 296: 221-27.
13. Yamaguchi Y, Mann DM, Ruoslahti E. Negative regulation of transforming growth factor-beta by the proteoglycan decorin. Nature 1990; 346: 281-84.
14. Iozzo RV, Moscatello DK, McQuillan DJ, Eichstetter I. Decorin is a biological ligand for the epidermal growth factor receptor. J Biol Chem 1999; 274: 4489-92.
15. Goldoni S, Humphries A, Nystrom A, et al. Decorin is a novel antagonistic ligand of the Met receptor. J Cell Biol 2009; 185: 743-54.
16. Svensson L, Heinegard D, Oldberg A. Decorin-binding sites for collagen type I are mainly located in leucine-rich repeats 4-5. J Biol Chem 1995; 270: 20712-16.
17. Kalamajski S, Aspberg A, Oldberg A. The decorin sequence SYIRIADTNIT binds collagen type I. J Biol Chem 2007; 282: 16062-67.
18. Vogel KG, Paulsson M, Heinegard D. Specific inhibition of type I and type II collagen fibrillogenesis by the small proteoglycan of tendon. Biochem J 1984; 223: 587-597.
19. Bidanset DJ, Guidry C, Rosenberg LC, Choi HU, Timpl R, Hook M. Binding of the proteoglycan decorin to collagen type VI. J Biol Chem 1992; 267: 5250-56.
20. Font B, Eichenberger D, Rosenberg LM, van der Rest M. Characterization of the interactions of type XII collagen with two small proteoglycans from fetal bovine tendon, decorin and fibromodulin. Matrix Biol 1996; 15: 341-348.
21. Iozzo RV. Matrix proteoglycans: from molecular design to cellular function. Annu Rev Biochem 1998; 67: 609-52.
22. Zhang G, Ezura Y, Chervoneva I, et al. Decorin regulates assembly of collagen fibrils and acquisition of biomechanical properties during tendon development. J Cell Biochem 2006; 98: 1436-49.
23. Kresse H, Rosthoj S, Quentin E, et al. Glycosaminoglycan- free small proteoglycan core protein is secreted by fibroblasts from a patient with a syndrome resembling progeroid. Am J Hum Genet 1987; 41: 436-53.
24. Bodo M, Baroni T, Carinci F, et al. TGFbeta isoforms and decorin gene expression are modified in fibroblasts obtained from non-syndromic cleft lip and palate subjects. J Dent Res 1999; 78: 1783-90.
25. Krull NB, Zimmermann T, Gressner AM. Spatial and temporal patterns of gene expression for the proteoglycans biglycan and decorin and for transforming growth factor-beta 1 revealed by in situ hybridization during experimentally induced liver fibrosis in the rat. Hepatology 1993; 18: 581-89.
26. Harper JR, Spiro RC, Gaarde WA, et al. Role of transforming growth factor beta and decorin in controlling fibrosis. Methods Enzymol 1994; 245: 241-54.
27. Hildebrand A, Romarís M, Rasmussen LM, et al. Interaction of the small interstitial proteoglycans biglycan, decorin and fibromodulin with transforming growth factor beta. Biochem J 1994; 302: 527-34.
28. Merline R, Lazaroski S, Babelova A, et al. Decorin deficiency in diabetic mice: aggravation of nephropathy due to overexpression of profibrotic factors, enhanced apoptosis and mononuclear cell infiltration. J Physiol Pharmacol 2009; 60: 5-13.
29. Plaisier M, Kapiteijn K, Koolwijk P, et al. Involvement of membrane-type matrix metalloproteinases (MT-MMPs) in capillary tube formation by human endometrial microvascular endothelial cells: role of MT3-MMP. J Clin Endocrinol Metab 2004; 89: 5828-36.
30. Hassell JR, Birk DE. The molecular basis of corneal transparency. Exp Eye Res 2010; 91: 326-35.
31. Michelacci YM. Collagens and proteoglycans of the corneal extracellular matrix. Braz J Med Biol Res 2003; 36: 1037-46.
32. Bredrup C, Knappskog PM, Majewski J, Rodahl E, Boman H. Congenital stromal dystrophy of the cornea caused by a mutation in the decorin gene. Invest Ophthalmol Vis Sci 2005; 46: 420-26.
33. Jester JV, Barry-Lane PA, Cavanagh HD, Petroll WM. Induction of alpha-smooth muscle actin expression and myofibroblast transformation in cultured corneal keratocytes. Cornea 1996; 15: 505-16.
34. Toole BP. Solubility of collagen fibrils formed in vitro in the presence of sulphated acid mucopolysaccharide-protein. Nature 1969; 222: 872-73.
35. Schaefer L, Iozzo RV. Biological functions of the small leucine-rich proteoglycans: from genetics to signal transduction. J Biol Chem 2008; 283: 21305-09.
36. Weber IT, Harrison RW, Iozzo RV. Model structure of decorin and implications for collagen fibrillogenesis. J Biol Chem 1996; 271: 31767-70.
37. Scott PG, McEwan PA, Dodd CM, Bergmann EM, Bishop PN, Bella J. Crystal structure of the dimeric protein core of decorin, the archetypal small leucine-rich repeat proteoglycan. Proc Natl Acad Sci USA 2004; 101: 15633-8.
38. Roughley PJ. The structure and function of cartilage proteoglycans. Eur Cell Mater 2006; 12: 92-101.
39. Chopra RK. Pearson CH, Pringle GA, Fackre DS, Scott PG. Dermatan sulphate is located on serine-4 of bovine skin proteodermatan sulphate. Biochem J 1985; 232: 77.
40. Fisher LW, Termine JD, Young MF. Deduced protein sequence of bone small proteoglycan I (biglycan) shows homology with proteoglycan II (decorin) and several nonconnective tissue proteins in a variety of species. J Biol Chem 1989; 264: 4571-76.
41. McEwan PA, Scott PG, Bishop PN, Bella J. Structural correlations in the family of small leucine-rich repeat proteins and proteoglycans. J Struct Biol 2006; 155: 294-305.
42. Orgel JP, Eid A, Antipova O, Bella J, Scott JE. Decorin core protein (decoron) shape complements collagen fibril surface structure and mediates its binding. PLoS One 2009; 4: e7028.
43. Grover J, Chen X-N, Korenberg JR, Roughley PJ. The human lumican gene. Organization, chromosomal location, and expression in articular cartilage. J Biol Chem 1995; 270:21942-49.
44. Fransson LA, Belting M, Jönsson M, Mani K, Moses J, Oldberg A. Biosynthesis of decorin and glypican. Matrix Biol 2000; 19: 367-76.
45. Tanihara H, Inatani M, Koga T, Yano T, Kimura A. Proteoglycans in the eye. Cornea 2002; 21: S62-9.
46. Macri L, Silverstein D, Clark RA. Growth factor binding to the pericellular matrix and its importance in tissue engineering. Adv Drug Deliv Rev 2007; 59: 1366-81.
47. Blaschke UK, Hedbom E, Bruckner P. Distinct isoforms of chicken decorin contain either one or two dermatan sulfate chains. J Biol Chem 1996; 271: 30347-53.
48. Scott PG, Dodd CM, Pringle GA. Mapping the locations of the epitopes of five monoclonal antibodies to the core protein of dermatan sulfate proteoglycan II (decorin). J Biol Chem 1993; 268: 11558-64.
49. Scott JE. Proteodermatan and proteokeratan sulfate (decorin, lumican/fibromodulin) proteins are horseshoe shaped. Implications for their interactions with collagen. Biochemistry 1996; 35: 8795-99.
50. Santra M, Danielson KG, Iozzo RV. Structural and functional characterization of the human decorin gene promoter. A homopurine-homopyrimidine S1 nuclease-sensitive region is involved in transcriptional control. J Biol Chem 1994; 269: 579-87.
51. Mauviel A, Santra M, Chen YQ, Uitto J, Iozzo RV. Transcriptional regulation of decorin gene expression. Induction by quiescence and repression by tumor necrosis factor-alpha. J Biol Chem 1995; 270: 11692-700.
52. Border WA, Okuda S, Languino LR, Ruoslahti E. Transforming growth factor-beta regulates production of proteoglycans by mesangial cells. Kidney Int 1990; 37: 689-95.
53. Funderburgh JL, Hevelone ND, Roth MR, et al. Decorin and biglycan of normal and pathologic human corneas. Invest Ophthalmol Vis Sci 1998; 39: 1957-64.
54. Moses J, Oldberg A, Eklund E, Fransson LA. Biosynthesis of the proteoglycan decorin -- identification of intermediates in galactosaminoglycan assembly. Eur J Biochem 1997; 248:767-74.
55. Cheng F, Heinegard D, Malmstrom A, Schmidtchen A, Yoshida K, Fransson LA. Patterns of uronosyl epimerization and 4-/6-O-sulphation in chondroitin/dermatan sulphate from decorin and biglycan of various bovine tissues. Glycobiology 1994; 4: 685-96.
56. Maccarana M, Kalamajski S, Kongsgaard M, Magnusson SP, Oldberg A, Malmstrom A. Dermatan sulfate epimerase 1- deficient mice have reduced content and changed distribution of iduronic acids in dermatan sulfate and an altered collagen structure in skin. Mol Cell Biol 2009; 29: 5517-28.
57. Gallagher JT, Gasiunas N, Schor SL. Specific association of iduronic acid-rich dermatan sulphate with the extracellular matrix of human skin fibroblasts cultured on collagen gels. Biochem J 1983; 215: 107-16.
58. Kalamajski S, Oldberg A. The role of small leucine-rich proteoglycans in collagen fibrillogenesis. Matrix Biol 2010; 29: 248-53.
59. Fleischmajer R, Fisher LW, MacDonald ED, Jacobs L Jr, Perlish JS, Termine JD. Decorin interacts with fibrillar collagen of embryonic and adult human skin. J Struct Biol 1991; 106: 82-90.
60. Sampaio Lde O, Bayliss MT, Hardingham TE, Muir H. Dermatan sulphate proteoglycan from human articular cartilage. Variation in its content with age and its structural comparison with a small chondroitin sulphate proteoglycan from pig laryngeal cartilage. Biochem J 1988; 254: 757-64.
61. Pringle GA, Dodd CM. Immunoelectron microscopic localization of the core protein of decorin near the d and e bands of tendon collagen fibrils by use of monoclonal antibodies. J Histochem Cytochem 1990; 38: 1405-11.
62. Brandan E, Cabello-Verrugio C, Vial C. Novel regulatory mechanisms for the proteoglycans decorin and biglycan during muscle formation and muscular dystrophy. Matrix Biol 2008; 27: 700-8.
63. Wu H, Jiang W, Zhang Y, et al. Regulation of intracellular decorin via proteasome degradation in rat mesangial cells. J Cell Biochem 2010; 111: 1010-9.
64. Nash MA, Deavers MT, Freedman RS. The expression of decorin in human ovarian tumors. Clin Cancer Res 2002; 8: 1754-60.
65. Imai K, Hiramatsu A, Fukushima D, Pierschbacher MD, Okada Y. Degradation of decorin by matrix metalloproteinases: identification of the cleavage sites, kinetic analyses and transforming growth factor-beta1 release. Biochem J 1997; 322: 809-14.
66. Schonherr E, Levkau B, Schaefer L, Kresse H, Walsh K. Decorin-mediated signal transduction in endothelial cells. Involvement of Akt/protein kinase B in up-regulation of p21(WAF1/CIP1) but not p27(KIP1). J Biol Chem 2001; 276: 40687-92.
67. De Luca A, Santra M, Baldi A, Giordano A, Iozzo RV. Decorin-induced growth suppression is associated with up- regulation of p21, an inhibitor of cyclin-dependent kinases. J Biol Chem 1996; 271: 18961-65.
68. Chakravarti S. Focus on molecules: keratocan (KERA). Exp Eye Res 2006; 82: 183-14.
69. Blochberger TC, Cornuet PK, Hassell JR. Isolation and partial characterization of lumican and decorin from adult chicken corneas. A keratan sulfate-containing isoform of decorin is developmentally regulated. J Biol Chem 1992; 267: 20613-19.
70. Song J, Lee YG, Houston J, et al. Neonatal corneal stromal development in the normal and lumican-deficient mouse. Invest Ophthalmol Vis Sci 2003; 44: 548-57.
71. Koga T, Inatani M, Hirata A, et al. Expression of a chondroitin sulfate proteoglycan, versican (PG-M), during development of rat cornea. Curr Eye Res 2005; 30: 455-63.
72. Funderburgh JL, Chandler JW. Proteoglycans of rabbit corneas with nonperforating wounds. Invest Ophthalmol Vis Sci 1989; 30: 435-42.
73. Zhang G, Chen S, Goldoni S, et al. Genetic evidence for the coordinated regulation of collagen fibrillogenesis in the cornea by decorin and biglycan. J Biol Chem 2009; 284: 8888-97.
74. Wu F, Lee S, Schumacher M, Jun A, Chakravarti S. Differential gene expression patterns of the developing and adult mouse cornea compared to the lens and tendon. Exp Eye Res 2008; 87: 214-25.
75. Mimura T, Han KY, Onguchi T, et al. MT1-MMP-mediated cleavage of decorin in corneal angiogenesis. J Vasc Res 2009; 46: 541-50.
76. Mohan RR, Stapleton WM, Sinha S, Netto MV, Wilson SE. A novel method for generating corneal haze in anterior stroma of the mouse eye with the excimer laser. Exp Eye Res 2008; 86: 235-40.
77. Du Y, Carlson EC, Funderburgh ML, et al. Stem cell therapy restores transparency to defective murine corneas. Stem Cells 2009; 27: 1635-42.
78. Ayad S, Boot-handford RP, Humpries MJ. The Extracellular Matrix Facts Book. San Diego: Academic Press, 1998.
79. Krusius T, Ruoslahti E. Primary structure of an extracellular matrix proteoglycan core protein deduced from cloned cDNA. Proc Natl Acad Sci USA 1986; 83: 7683-87.
80. Ruoslahti E. Structure and biology of proteoglycans. Annu Rev Cell Biol 1988; 4: 229-55.
81. Danielson KG, Baribault H, Holmes DF, Graham H, Kadler KE, Iozzo RV. Targeted disruption of decorin leads to abnormal collagen fibril morphology and skin fragility. J Cell Biol 1997; 136: 729-43.
82. Seidler DG, Schaefer L, Robenek H, Iozzo RV, Kresse H, Schonherr E. A physiologic three-dimensional cell culture system to investigate the role of decorin in matrix organisation and cell survival. Biochem Biophys Res Commun 2005; 332: 1162-70.
83. Winnemoller M, Schon P, Vischer P, Kresse H. Interactions between thrombospondin and the small proteoglycan decorin: interference with cell attachment. Eur J Cell Biol 1992; 59: 47-55.
84. Ferdous Z, Peterson SB, Tseng H, Anderson DK, Iozzo RV, Grande-Allen KJ. A role for decorin in controlling proliferation, adhesion, and migration of murine embryonic fibroblasts. J Biomed Mater Res A 2010; 93: 419-28.
85. Geng Y, McQuillan D, Roughley PJ. SLRP interaction can protect collagen fibrils from cleavage by collagenases. Matrix Biol 2006; 25: 484-491.
86. Ruhland C, Schonherr E, Robenek H, et al. The glycosaminoglycan chain of decorin plays an important role in collagen fibril formation at the early stages of fibrillogenesis. FEBS J 2007; 274: 4246-55.
87. Chakravarti S, Magnuson T, Lass JH, Jepsen KJ, LaMantia C, Carroll H. Lumican regulates collagen fibril assembly: skin fragility and corneal opacity in the absence of lumican. J Cell Biol 1998; 141: 1277-86.
88. Funderburgh JL, Funderburgh ML, Mann MM, Corpuz L, Roth MR. Proteoglycan expression during transforming growth factor beta-induced keratocyte-myofibroblast transdifferentiation. J Biol Chem 2001; 276: 44173-8.
89. Whitcher JP, Srinivasan M, Upadhyay MP. Corneal blindness: a global perspective. Bull World Health Org 2001; 79: 214-21.
90. Congdon N, O'Colmain B, Klaver CC, et al. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol 2004; 122: 477-85.
91. Foster A, Resnikoff S. The Impact of Vision 2020 on Global Blindness. Eye 2005; 19: 1133-5.
92. Fong CS. Refractive surgery: the future of perfect vision? Singapore Med J 2007; 48: 709-18.
93. Sakimoto T, Rosenblatt MI, Azar DT. Laser eye surgery for refractive errors. Lancet 2006; 367: 1432-47.
94. Seiler T, McDonnell PJ. Excimer laser photorefractive keratectomy. Surv Ophthalmol 1995; 40: 89-118.
95. Jester JV, Petroll WM, Cavanagh HD. Corneal stromal wound healing in refractive surgery: the role of myofibroblasts. Prog Retin Eye Res 1999, 18: 311-56.
96. Imanishi J, Kamiyama K, Iguchi I, Kita M, Sotozono C, Kinoshita S. Growth factors: importance in wound healing and maintenance of transparency of the cornea. Prog Retin Eye Res 2000; 19: 113-29.
97. Hausser H, Groning A, Hasilik A, Schonherr E, Kresse H. Selective inactivity of TGF-beta/decorin complexes. FEBS Lett 1994; 353: 243-45.
98. Markmann A, Hausser H, Schonherr E, Kresse H. Influence of decorin expression on transforming growth factor-beta- mediated collagen gel retraction and biglycan induction. Matrix Biol 2000; 19: 631-6.
99. Rodahl E, Van Ginderdeuren R, Knappskog PM, Bredrup C, Boman H. A second decorin frame shift mutation in a family with congenital stromal corneal dystrophy. Am J Ophthalmol 2006; 142: 520-1.
100. Bredrup C, Stang E, Bruland O, et al. Decorin accumulation contributes to the stromal opacities found in congenital stromal corneal dystrophy. Invest Ophthalmol Vis Sci 2010; 51: 5578-82.
101. Reinboth B, Thomas J, Hanssen E, Gibson MA. Beta ig-h3 interacts directly with biglycan and decorin, promotes collagen VI aggregation, and participates in ternary complexing with these macromolecules. J Biol Chem 2006; 281: 7816-24.
102. Plaas AH, West LA, Thonar EJ, et al. Altered fine structures of corneal and skeletal keratan sulfate and chondroitin/dermatan sulfate in macular corneal dystrophy. J Biol Chem 2001; 276: 39788-96.
103. Aldave AJ, Edward DP, Park AJ, Raber IM, Eagle RC Jr. Central discoid corneal dystrophy. Cornea 2002; 21: 739-44.
104. Nomura Y. Structural change in decorin with skin aging. Connect Tissue Res 2006; 47: 249-55.
105. Roughley PJ, Melching LI, Recklies AD. Changes in the expression of decorin and biglycan in human articular cartilage with age and regulation by TGF-beta. Matrix Biol 1994; 14: 51-9.
106. Teicher BA, Ikebe M, Ara G, Keyes SR, Herbst RS. Transforming growth factor-beta 1 overexpression produces drug resistance in vivo: reversal by decorin. In vivo 1997; 11: 463-472.
107. Grant DS, Yenisey C, Rose RW, Tootell M, Santra M, Iozzo RV. Decorin suppresses tumor cell-mediated angiogenesis. Oncogene 2002; 21: 4765-77.
108. Santra M, Skorski T, Calabretta B, Lattime EC, Iozzo RV. De novo decorin gene expression suppresses the malignant phenotype in human colon cancer cells. Proc Natl Acad Sci USA 1995; 92: 7016-20.
109. Reed CC, Gauldie J, Iozzo RV. Suppression of tumorigenicity by adenovirus-mediated gene transfer of decorin. Oncogene 2002; 21: 3688-95.
110. Border WA, Noble NA, Yamamoto T, et al. Natural inhibitor of transforming growth factor-beta protects against scarring in experimental kidney disease. Nature 1992; 360: 361-64.
111. Isaka Y, Brees DK, Ikegaya K, et al. Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney. Nat Med 1996; 2: 418-423.
112. Kolb M, Margetts PJ, Sime PJ, Gauldie J. Proteoglycans decorin and biglycan differentially modulate TGF-beta- mediated fibrotic responses in the lung. Am J Physiol Lung Cell Mol Physiol 2001; 280: L1327-34.
113. Wahab NA, Parker S, Sraer JD, Mason RM. The decorin high glucose response element and mechanism of its activation in human mesangial cells. J Am Soc Nephrol 2000; 11: 1607-19.
114. Williams KJ, Qiu G, Usui HK, et al. Decorin deficiency enhances progressive nephropathy in diabetic mice. Am J Pathol 2007; 171: 1441-50.
115. Schaefer L, Raslik I, Grone HJ, et al. Small proteoglycans in human diabetic nephropathy: discrepancy between glomerular expression and protein accumulation of decorin, biglycan, lumican, and fibromodulin. FASEB J 2001; 15: 559-61.
116. Ophascharoensuk V, Fero ML, Hughes J, Roberts JM, Shankland SJ. The cyclin-dependent kinase inhibitor p27 Kip1 safeguards against inflammatory injury. Nat Med 1998; 4: 575-80.
117. Melrose J, Fuller ES, Roughley PJ, et al. Fragmentation of decorin, biglycan, lumican and keratocan is elevated in degenerate human meniscus, knee and hip articular cartilages compared with age-matched macroscopically normal and control tissues. Arthritis Res Ther 2008; 10: R79.
118. Fukushima K, Badlani N, Usas A, Riano F, Fu F, Huard J. The use of an antifibrosis agent to improve muscle recovery after laceration. Am J Sports Med 2001; 29: 394-402.
119. Szurman P, Grisanti S, Ziemssen F, et al. Adjuvant decorin therapy for wound healing suppression after filtrating glaucoma surgery. Invest Ophthalmol Vis Sci 2003; 44: E-Abstract 1202.
120. Grisanti S, Szurman P, Warga M, et al. Decorin modulates wound healing in experimental glaucoma filtration surgery: a pilot study. Invest Ophthalmol Vis Sci 2005; 46: 191-6.
121. von Marschall Z, Fisher LW. Decorin is processed by three isoforms of bone morphogenetic protein-1 (BMP1). Biochem Biophys Res Commun 2010; 391: 1374-8.
122. Shimizu-Hirota R, Sasamura H, Kuroda M, Kobayashi E, Hayashi M, Saruta T. Extracellular matrix glycoprotein biglycan enhances vascular smooth muscle cell proliferation and migration. Circ Res 2004; 94: 1067-74.
123. Biglari A, Bataille D, Naumann U, et al. Effects of ectopic decorin in modulating intracranial glioma progression in vivo, in a rat syngeneic model. Cancer Gene Ther 2004; 11: 721-32.
124. Seitz B, Moreira L, Baktanian E, et al. Retroviral vector- mediated gene transfer into keratocytes in vitro and in vivo. Am J Ophthalmol 1998; 126: 630-9.